| Similar Articles |
|---|
 |
The Motley Fool
September 30, 2011
Brian Orelli |
We Don't Care if It's the First Lupus Drug in 50 Years The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta.   |
The Motley Fool
August 5, 2011
Brian Orelli |
Still Want to Be the Next Dendreon? The biotech market is punished. |
The Motley Fool
March 17, 2011
Brian Orelli |
Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping. |
The Motley Fool
December 30, 2011
Brian Orelli |
A Bad Year for the 6,300% Miracle Human Genome Sciences falls from grace. |
The Motley Fool
July 20, 2009
Brian Orelli |
Overnight Triple! Yee-Haw! The joys of owning biotech companies. The latest beneficiary, Human Genome Sciences, is up more than 220% today because Benlysta, their new drug for lupus, works. |
The Motley Fool
June 14, 2010
Brian Orelli |
No Approval? No Problem! Investors shrug off Human Genome's news about its hepatitis C drug Zalbin. |
The Motley Fool
December 9, 2008
Brian Orelli |
Human Genome's Hep C Drug Is Halfway Home One trial down, one to go for Human Genome Sciences. |
The Motley Fool
August 30, 2007
Brian Lawler |
Human Genome Steps Forward Human Genome Sciences investors got good news as the drugmaker took a quicker-than-expected step in its journey to get its lead drug, hepatitis C treatment Albuferon, on the path to FDA approval. |
The Motley Fool
October 5, 2005
Stephen D. Simpson |
Lupus Trials Spook Investors Lupus is a high-risk, high-reward indication, and today's disappointing trial results aren't the end of the story for Human Genome Sciences. Aggressive and experienced investors might want to take a look at this one, but this is clearly not a stock for the faint of heart. |
The Motley Fool
June 28, 2005
Charly Travers |
Growth Around the Corner? Despite a thin pipeline, small biotech Cubist Pharmaceuticals is hoping to ride the wave of prosperity. Investors, take note. |
The Motley Fool
December 28, 2007
Brian Lawler |
Cubist's Cheap Call Option As a Christmas Eve present to itself, Cubist Pharmaceuticals follows through on its October option to purchase Illumigen. |
The Motley Fool
July 27, 2011
Brian Orelli |
Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication. |
The Motley Fool
July 7, 2011
Brian Orelli |
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo. |
The Motley Fool
April 14, 2011
Brian Orelli |
Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year. |
The Motley Fool
October 31, 2011
Brian Orelli |
Gunning for the Leaders Hepatitis C drugs take center stage. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
December 30, 2010
Brian Orelli |
This NICE Deal Could Foreshadow 2011 Value-based pricing is coming. The only way to encourage lower drug costs is to get the end user to pay the cost directly. |
The Motley Fool
August 11, 2011
Brian Orelli |
Dendreon's a Broken IPO, Again $10 isn't really a magical number. |
The Motley Fool
October 28, 2011
Brian Orelli |
Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug. |
The Motley Fool
September 11, 2007
Brian Lawler |
Score One for Pharmasset Shares of Pharmasset were up after the company announced impressive results for its Hepatitis C virus drug candidate R7128. Investors should continue to watch closely. |
The Motley Fool
October 26, 2011
Brian Orelli |
Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. |
The Motley Fool
May 29, 2008
Brian Lawler |
Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing. |
The Motley Fool
January 19, 2012
Brian Orelli |
New Hep C Data Impressive, but It's Not There Yet All-oral treatment still has a ways to go. |
The Motley Fool
October 30, 2009
Brian Orelli |
Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening. |
The Motley Fool
November 17, 2010
Brian Orelli |
52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval. |
The Motley Fool
February 27, 2009
Brian Orelli |
Waiting to Inhale Human Genome Sciences is guiding for revenue of $250 million this year compared to less than $50 million last year, thanks to its sale of anthrax emergency treatment ABthrax to the government. |
The Motley Fool
July 27, 2011
Alexander Crawford |
Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve? |
The Motley Fool
April 6, 2011
Brian Orelli |
Killing Bacteria With the Help of a Friend Optimer Pharmaceuticals has signed up Cubist Pharmaceuticals as a marketing partner for at least the next two years. |
The Motley Fool
January 9, 2012
David Williamson |
Inhibitex Is an Instant Double Some takeout rumors do come true. |
The Motley Fool
January 30, 2009
Brian Orelli |
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients. |
The Motley Fool
November 25, 2011
Brian Orelli |
7 Black Friday Biotech Bargains Get in at the right time to maximize your returns. |
The Motley Fool
July 22, 2011
Brian Orelli |
It's How You Finish That Matters Human Genome Sciences gained approval of the first drug developed for lupus in half a century, but in its first full quarter on the market Benlysta was uninspiring. |
The Motley Fool
October 31, 2007
Brian Lawler |
The Next Hepatitis C Blockbuster? Never before have there been so many new drugs in development to treat Hepatitis C. Which companies have the compounds most likely to win this race? Investors, take note. |
The Motley Fool
August 4, 2008
Brian Lawler |
Vertex on the Verge of Victory Like the majority of biotech drugmakers, Vertex's financials proved less crucial in the second quarter than the clinical trial results from the drugmaker's pipeline. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007. |
The Motley Fool
October 20, 2011
Travis Hoium |
Cubist Pharmaceuticals Shares Popped: What You Need to Know Shares of Cubist Pharmaceuticals jumped 10% today after the company released earnings. |
The Motley Fool
November 21, 2011
David Williamson |
Pharmasset Acquired, Shares Jump 85% Gilead Sciences buys Pharmasset and hepatitis C drug PSI-7977. |
Chemistry World
November 4, 2009
Phil Taylor |
New treatment hope for lupus patients GlaxoSmithKline and Human Genome Sciences' Benlysta (belimumab), works by blocking the production of autoantibodies by plasma B-cells, the immune system's primary antibody-producing cells. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
November 2, 2009
Brian Orelli |
Finally Convinced? Benlysta Works! Human Genome Sciences succeeds where others have failed. |
The Motley Fool
November 30, 2011
David Williamson |
Health Care's 5 Worst November Flops These stocks had a terrible month. |
The Motley Fool
April 19, 2004
Charly Travers |
4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry. |
The Motley Fool
January 29, 2007
Brian Lawler |
No Dicey Results for Cubist The stock price may be down, but Cubist Pharmaceuticals is looking strong. |
The Motley Fool
June 15, 2011
Selena Maranjian |
Make Money in Biotech the Easy Way There's no need to guess which biotech company will perform best with the SPDR S&P Biotech ETF. |
The Motley Fool
July 13, 2011
David Williamson |
Roundtable: The Biggest Risks in Biotech Three biotech companies to steer clear of. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
The Motley Fool
November 21, 2011
David Williamson |
Market Volatility = Biotech Opportunity Gilead buys Pharmasset, Spectrum gets a break, and Eylea's approved. |
The Motley Fool
November 7, 2011
David Williamson |
Health-Care News You Can't Afford to Miss Highlighting the day's health-care stories: FDA approval for Johnson & Johnson... Inhibitex kept its streak of double-digit gains alive with another 14% surge today... 13% plunge for Optimer Pharmaceuticals... |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
